Their research has been published in Science Advances, titled "Coin-sized, fully integrated, and minimally invasive ...

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

The FDA has cleared Senseonics and Ascensia Diabetes Care's Eversense 365 Glucose Monitoring System. This system is designed for Type 1 and Type 2 diabetics 18 and older and will be the first ...

A new study from researchers at the BU Chobanian & Avedisian School of Mediicne have that found that non-diabetic individuals using continuous glucose monitoring sensors  spend a much larger period of ...

Senseonics Holdings, Inc. , a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

Understanding glucose and how your body processes it can provide important personal insights that may help you feel your best ...

New Zealand Society for the Study of Diabetes (NZSSD) welcomes Pharmac’s decision to fund continuous glucose monitors and insulin pumps, which allow automated insulin delivery, for people with type 1 ...

DexCom, Inc. , the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's groundbreaking NIL ...

Medical technology companies Senseonics and Ascensia Diabetes Care have announced receipt of the US Food and Drug ...

A Stourbridge woman who has had type one diabetes for more than 50 years has written a book about her experiences.

A Stourbridge woman who has had type one diabetes for more than 50 years has written a book about her experiences.